Impact of IL28B gene polymorphisms on interferon- 3 plasma levels during pegylated interferon- /ribavirin therapy for chronic hepatitis C in patients coinfected with HIV | Zendy

Norma Rallón | Zendy; Vincent Soriano | Zendy; Susanggie | Zendy; Clara Restrepo | Zendy; John G. McHutchison | Zendy; Eugenia Vispo | Zendy; José M. Benito | Zendy

Open Access

Impact of IL28B gene polymorphisms on interferon- 3 plasma levels during pegylated interferon- /ribavirin therapy for chronic hepatitis C in patients coinfected with HIV

Author(s) -

Norma Rallón,

Vincent Soriano,

Susanggie,

Clara Restrepo,

John G. McHutchison,

Eugenia Vispo,

José M. Benito

Publication year - 2012

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkr598

Subject(s) - ribavirin , pegylated interferon , medicine , gastroenterology , hepatitis c , immunology , hepatitis c virus , alpha interferon , interferon , virus

The mechanism explaining the strong association between IL28B rs12979860 polymorphisms and treatment outcome in chronic hepatitis C remains unclear. We explore whether IL28B protein [interferon (IFN)-λ3] plasma levels may vary according to IL28B genotype and/or following pegylated IFN-α/ribavirin therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research